A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Avatrombopag (Primary)
- Indications Liver disorders; Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 03 Sep 2014 New trial record